Intelligent Bio Solutions Inc. (INBS) AI Stock Analysis
INBS AI stock analysis summary
AI ResearchIntelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical devices company focused on biosensor platforms. While FY2026 revenue increased 38.1% to $4.2M, the company posted a net income of -$12.4M and negative free cash flow of -$12.1M. The stock closed at $1.50 after an 85.4% decline over the past year.
- Market cap
- $5.0M
- Revenue (TTM)
- $4.2M
- P/E
- —
- 1Y return
- -85.4% S&P 500 16.8%
- Avg. target
- $12.00 700.0% vs last close
Bull case
- Revenue increased 38.1% in FY2026 to $4.2M, with gross margin expanding to 48.6%.
- Analyst estimates project revenue to increase to $6.1M in FY2027 and $8.8M in the following fiscal year.
- The balance sheet holds $4.0M in cash and short-term investments, providing a positive net cash position of $2.2M.
Bear case
- The company burned -$12.1M in free cash flow in FY2026 while generating a net loss of -$12.4M.
- Share count expanded by 3805.4% over a 5-year span, highlighting significant past equity dilution.
- The stock has dropped 85.4% over the past year and trades at $1.50, close to its 52-week low of $1.35.
What Intelligent Bio Solutions does
Intelligent Bio Solutions Inc., based in New York, New York, is a life sciences company developing non-invasive, real-time monitoring and diagnostic solutions. Formerly called GBS Inc. until its rebrand in October 2022, it operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd with 59 employees. Its flagship Saliva Glucose Biosensor uses organic thin-film transistor technology to monitor glucose for diabetes management. The company is also developing a SARS-CoV-2 Biosensor to complement RNA virus detection tests. Its platform is expanding toward diverse modalities, including biochemistry, immunology, tumor markers, hormones, and nucleic acid tests.
Growth and profitability
Intelligent Bio Solutions generated FY2026 revenue of $4.2M, up 38.1% from $3.1M in FY2025. Between FY2020 and FY2026, revenue increased at an 86.1% compound annual growth rate. Gross margin reached 48.6% in FY2026, improving from 40.8% in FY2025 and 45.8% in FY2024. However, operating margin remained deeply negative at -299.1% in FY2026, alongside net income of -$12.4M and a net margin of -294.9%. Research and development expenses were $3.4M in FY2026, up from $2.4M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 35.8% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, the company held $4.0M in cash and short-term investments against total debt of $1.8M, resulting in net cash of $2.2M. Total assets stood at $11.9M and shareholders' equity was $5.5M. The company reported a current ratio of 1.44 and a debt-to-equity ratio of 0.33. Operating cash flow in FY2026 was -$11.9M, and capital expenditures were $125,731, yielding free cash flow of -$12.1M. Share count increased 3805.4% over five years.
Valuation and performance
With a market cap of $5.0M and enterprise value of $3.7M, INBS trades at a price-to-sales multiple of 1.2x and an EV to revenue multiple of 0.9x. These multiples compare to a price-to-sales ratio of 4.1x for the median of its US-listed Healthcare peers. Its price-to-book ratio is 1.1x. Over the past year, the stock fell 85.4%, compared to a 16.8% return for the S&P 500 (SPY). Over five years, the stock dropped 100.0% while SPY gained 83.0%. The stock trades 59.9% below its 200-day average.
What analysts expect
One analyst covers INBS with a Strong Buy rating. The mean price target is $12.00, which is 700.0% above the last close of $1.50. For the fiscal year ending June 30, 2027, the revenue estimate is $6.1M and the EPS estimate is -$5.18, representing an expected EPS growth of 38.6%. For the following fiscal year, revenue is projected at $8.8M with an EPS of -$4.06. INBS beat EPS estimates in 1 of the last 4 quarters. The next earnings date is November 11, 2026.
Key risks and what to watch
- Annual free cash flow was -$12.1M in FY2026, which exceeds the June 30, 2026 cash balance of $4.0M.
- Operating margin was -299.1% in FY2026, reflecting continued dependence on external funding for operations.
- The stock exhibits high market volatility, reflected in a beta of 4.30.
- Institutional ownership is relatively low at 5.5%, while insider holdings stand at 2.7%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this INBS AI stock analysis
This page is an AI-written research summary of Intelligent Bio Solutions Inc. (INBS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: INBS income statement, INBS balance sheet, INBS key metrics, INBS analyst forecast, INBS chart. See the INBS stock overview for the latest quote and news.
INBS AI stock analysis FAQ
What is Intelligent Bio Solutions Inc.'s core business?
Intelligent Bio Solutions Inc. is a medical devices firm that develops non-invasive biosensor diagnostic tests, including the Saliva Glucose Biosensor and the SARS-CoV-2 Biosensor.
What were the revenues and profits of INBS in FY2026?
In FY2026, the company generated $4.2M in revenue, up 38.1% year-over-year. Net income was -$12.4M, resulting in a net margin of -294.9% and an EPS of -$5.87.
Does INBS pay a dividend?
No, Intelligent Bio Solutions Inc. does not pay a dividend.
What are analysts forecasting for INBS?
The single covering analyst gives INBS a Strong Buy rating with a mean price target of $12.00. For the fiscal year ending June 30, 2027, the consensus estimate calls for $6.1M in revenue and an EPS of -$5.18.